Long-Term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?

Basit Öğe Kaydı
dc.authoridKAYA, OZGE/0000-0001-8062-1664
dc.authoridKESKINKAYA, ZEYNEP/0000-0002-2982-3823
dc.contributor.authorKaya, Ozge
dc.contributor.authorKeskinkaya, Zeynep
dc.contributor.authorMermutlu, Selda Isik
dc.contributor.authorKilic, Sevilay Oguz
dc.contributor.authorOzturk, Sevgi
dc.date.accessioned2025-01-27T20:29:01Z
dc.date.available2025-01-27T20:29:01Z
dc.date.issued2023
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era. Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 infection. Methods: In this retrospective study, files of CSU patients using OMZ during the COVID-19 pandemic were reviewed in terms of demographic features, medical history including COVID-19 vaccination status, clinical characteristics, pretreatment laboratory parameters, duration, and dosing regimen of OMZ treatment. Patients with a history of COVID-19 infection while on OMZ therapy and patients without COVID-19 history were compared with respect to these parameters. The urticaria activations following COVID-19 infection or vaccination were also recorded. Results: Sixty-eight patients with CSU (female:male ratio = 1.8:1; mean age = 47.2 +/- 15.1 years) continued to receive OMZ treatment. The median duration of OMZ treatment was 12 months (range: 6-60). Twelve patients (17.6%) were diagnosed with COVID-19 showing no exacerbation in urticaria. The duration of OMZ treatment was significantly higher in the group with COVID-19 infection history compared to patients with no history of COVID-19 (P = 0.01). Among 51 patients (75%) vaccinated against COVID-19, urticaria activation occurred in 4 patients without any recurrence following booster vaccinations. Conclusions: Considering the likelihood of increased COVID-19 infection risk in the setting of long-term OMZ in CSU patients, the duration of OMZ therapy might be kept at a minimum, or a temporary interruption of the treatment period might be preferred, particularly in high-risk patients regarding COVID-19.
dc.identifier.doi10.5826/dpc.1303a145
dc.identifier.issn2160-9381
dc.identifier.issue3
dc.identifier.pmid37557113
dc.identifier.urihttps://doi.org/10.5826/dpc.1303a145
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22782
dc.identifier.volume13
dc.identifier.wosWOS:001074574200012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMattioli 1885
dc.relation.ispartofDermatology Practical & Conceptual
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectangiotensin-converting enzyme 2
dc.subjectchronic spontaneous urticaria
dc.subjectCOVID-19
dc.subjectomalizumab
dc.subjectactivation
dc.titleLong-Term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu